$OTLK

Outlook Therapeutics, Inc. (OTLK) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Chief Financial Officer Transition On August 23, 2026, Outlook Therapeutics, Inc. (the “Company”) and Lawrence A. Kenyon, t

Outlook Therapeutics (OTLK) shares rose 21% after resubmitting its FDA application for Lytenava to treat nAMD, following a successful appeal. The FDA previously denied approval but now agrees no additional trials are needed. A decision is expected within 60 days. Lytenava, if approved, would be the first FDA-approved ophthalmic formulation of bevacizumab. The stock has fallen 50% over the past year.

Investing.com reported major US insider trades disclosed Friday. Buys: PAL director Rohit Lal bought $272.5k; OTLK director/10% owner Ghiath Sukhtian bought about 2.5M shares and warrants for ~$2.5M; CLPR director Sam Levinson bought ~$488.8k; OPFI CEO Todd Schwartz bought ~$144k; OPEN CEO Kasra Nejatian bought ~$100k. Sells: CRWV 10% owner Magnetar sold ~$231.6M then ~$213.8M; ANET CEO Ullal trust sales ~$119.3M; SEPN RA Capital sold $63.45M; KRYS director Rossi sold ~$8.23M.

Outlook Therapeutics (NASDAQ:OTLK) CEO Robert Jahr bought 151,515 shares and 151,515 warrants on Aug. 14, 2026 at a combined public offering price of $0.99 per unit. Each warrant lets him buy one share at $1.10, exercisable immediately, expiring Aug. 14, 2031. The company also reported a narrower fiscal Q3 adjusted net loss of $10.9M ($0.09/share) and prepares to launch FDA-approved eye drug LYTENAVA.

Outlook Therapeutics (OTLK) disclosed an SEC Schedule 13D amendment from GMS Ventures and Ghiath M. Sukhtian. After the August 2026 offering, GMS Ventures beneficially owns 24,617,320 shares plus 18,013,822 warrants, about 16.4% of outstanding shares. GMS bought 2,525,252 shares and warrants for about $2.5 million at $0.99 per unit; warrants exercise at $1.10.

Outlook Therapeutics (OTLK) said insider-linked GMS Ventures, tied to director and 10% owner Ghiath M. Sukhtian, bought 2,525,252 shares at $0.99 each in an underwritten public offering on Aug. 12, 2026. GMS Ventures also received 2,525,252 warrants with a $1.10 exercise price, exercisable immediately and expiring Aug. 14, 2031.

Sukhtian Ghiath M. purchased 2,525,252 indirectly-held shares of Outlook Therapeutics, Inc. (OTLK) at $0.99 ($2.50M total) on 2026-08-12. Filed jointly with GMS Ventures & Investments (Director).

Outlook Therapeutics (OTLK) CFO Lawrence A. Kenyon reported purchases on Aug. 14, 2026 tied to an underwritten public offering. He bought 101,010 shares of common stock and received 101,010 accompanying warrants. The combined offering price was $0.99 per share and warrant. Warrants are exercisable immediately at $1.10 and expire Aug. 14, 2031.

Outlook Therapeutics, Inc. (OTLK) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™ The only FDA-approved ophthalmic bevacizumab, LYTENAVA TM , addresses a significant need in the U.S. wet AMD market where

Outlook Therapeutics (Nasdaq: OTLK) reported Q3 FY2026 results ended June 30, 2026, with net loss of $20.3M ($0.15/share) versus $20.2M ($0.55/share) a year earlier. Adjusted net loss was $10.9M ($0.09/share). The company said FDA approval of LYTENAVA supports a planned U.S. launch before end-2026 and estimates potential U.S. sales exceeding $500M by 2030, plus a $51.1M public offering.